Abstract: SA-PO327
Patient Views Regarding Cannabis Use in CKD and Kidney Failure: A Survey Study
Session Information
- Hemodialysis and Frequent Dialysis: Potpourri
November 05, 2022 | Location: Exhibit Hall, Orange County Convention Center‚ West Building
Abstract Time: 10:00 AM - 12:00 PM
Category: Dialysis
- 701 Dialysis: Hemodialysis and Frequent Dialysis
Authors
- Collister, David Thomas, University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
- Whitlock, Reid, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
- Tennankore, Karthik K., Dalhousie University Faculty of Medicine, Halifax, Nova Scotia, Canada
- Tangri, Navdeep, University of Manitoba Max Rady College of Medicine, Winnipeg, Manitoba, Canada
- Goupil, Remi, Universite de Montreal, Montreal, Quebec, Canada
- Nadeau-Fredette, Annie-Claire, Universite de Montreal, Montreal, Quebec, Canada
- Davison, Sara N., University of Alberta Faculty of Medicine & Dentistry, Edmonton, Alberta, Canada
- Wald, Ron, University of Toronto Temerty Faculty of Medicine, Toronto, Ontario, Canada
- Walsh, Michael, McMaster University, Hamilton, Ontario, Canada
Background
Cannabis is frequently used recreationally and medicinally including for symptom management in patients with kidney disease.
Methods
We elicited the views of Canadian adults with kidney disease regarding their cannabis use. Participants were asked whether they would try cannabis for anxiety, depression, restless legs, itchiness, fatigue, chronic pain, decreased appetite, nausea/vomiting, sleep, cramps and other symptoms. The degree to which respondents considered cannabis for each symptom was assessed with a modified Likert scale ranging from 1-5 (anchored at 1 “definitely would not” and 5 being “definitely would”). Multilevel multivariable linear regression was used to identify respondent characteristics associated with considering cannabis for symptom control.
Results
Of 320 respondents, 290 (90.6%) were from in-person recruitment (27.3% response rate) and 30 (9.4%) responses were from online recruitment. 160/320 respondents (50.2%) had previously used cannabis including smoking (140, 87.5%), oils (69, 43.1%) and edibles (92, 57.5%). The most common reasons for previous cannabis use were recreation (84/160, 52.5%), pain alleviation (63/160, 39.4%) and sleep enhancement (56/160, 35.0%). Only 33.8% of previous cannabis users thought their physicians were aware of their cannabis use. >50% of respondents probably would or definitely would try cannabis for symptom control for all 10 symptoms. Characteristics independently associated with interest in trying cannabis for symptom control included symptom type (pain, sleep, restless legs), online respondent (ß 0.7, 95% CI 0.1-1.4) and previous cannabis use (ß 1.2, 95% CI 0.9, 1.5).
Conclusion
Many patients with kidney disease use cannabis and there is interest in trying cannabis for symptom control.